Murine_anti-interleukin-6_monoclonal_antibody_therapy_for_a_patient_with_plasma_cell_leukemia._A_patient_with_primary_plasma_cell_leukemia_resistant_to_chemotherapy_was_treated_for_2_months_with_daily_intravenous_injections_of_anti-interleukin-6_(IL-6)_monoclonal_antibodies_(MoAbs)._The_patient's_clinical_status_improved_throughout_the_treatment_and_no_major_side_effects_were_observed._Serial_monitoring_showed_blockage_of_the_myeloma_cell_proliferation_in_the_bone_marrow_(from_4.5%_to_0%_myeloma_cells_in_the_S-phase_in_vivo)_as_well_as_reduction_in_the_serum_calcium,_serum_monoclonal_IgG,_and_the_serum_C-reactive_protein_levels._The_serum_calcium_and_serum_monoclonal_IgG_corrected_by_approximately_30%,_whereas_the_C-reactive_protein_corrected_to_undetectable_levels_during_treatment._No_major_side_effects_developed,_although_both_platelet_and_circulating_neutrophil_counts_decreased_during_anti-IL-6_therapy._A_transient_immunization_was_detected_15_days_after_the_initiation_of_the_treatment,_which_could_explain_the_recovery_of_myeloma_cell_proliferation_after_2_months_of_treatment_(2%_myeloma_cells_in_the_S_phase)._In_conclusion,_this_first_anti-IL-6_clinical_trial_demonstrated_the_feasibility_of_injecting_anti-IL-6_MoAbs,_and_also_a_transient_tumor_cytostasis_and_a_reduction_in_IL-6-related_toxicities._It_gave_insight_into_the_major_biologic_activities_of_IL-6_in_vivo_and_may_serve_as_a_basis_for_further_development_of_anti-IL-6_therapy_in_myeloma_and_other_IL-6-related_diseases.